Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
autologous stored platelets · 1 trial · 1 indication
pharmacodynamic measurements of platelet function will be assessed at baseline, after 3 days administration of aspirin and clopidogrel (300 mg loading with aspirin and clopidogrel, maintenance with 100 mg aspirin and 75 mg clopidogrel, respectively) after retransfusion of stored platelets and 24 hours thereafter
| Arm | Type | Description |
|---|---|---|
| autologous stored platelets | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| autologous stored platelets | OTHER | Administration of autologous stored platelets |
| administration of autologous stored platelets | OTHER | administration of autologous stored platelets |
Inclusion Criteria: 1. Informed consent 2. Healthy volunteers, male or female (after exclusion of pregnancy if they are on birth control pill or have a contraceptive coil implanted) 3. Age of consent 4. Weight: 70 kg - 100 kg 5. Platelet count 240 000 to 440 000/µL 6. Hematocrit \> 40% 7. readiness...
Autologous stored platelets is an investigational therapy being studied for bleeding. It is in Phase 2 clinical development. The approach involves using a patient's own platelets, which are stored and then potentially used to manage bleeding. It is being developed by Novo Nordisk A/S.
Novo Nordisk A/S (ticker: NVO) is developing autologous stored platelets. The therapy is currently in Phase 2 clinical development for bleeding. It is an investigational product and has not been approved by regulatory authorities.
Autologous stored platelets is in Phase 2 clinical development. It is being studied for bleeding. The therapy is investigational and has not been approved. One Phase 2 trial has been completed, involving 6 participants.
Autologous stored platelets has one completed Phase 2 trial, NCT01248351, titled "Reversibility of Dual Antiplatelet Therapy by Platelets." The trial enrolled 6 participants with bleeding in Austria. It was an uncontrolled study that included healthy volunteers.
Autologous stored platelets refers to a patient's own platelets that are collected and stored for potential use. This approach is distinct from donor-derived platelet transfusions. The therapy is being investigated for bleeding and is in Phase 2 development by Novo Nordisk.